Litcius/Paper detail

Variation in neutrophil to lymphocyte ratio (NLR) as predictor of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (mNSCLC) patients treated with nivolumab

Audrey Simonaggio, Réza Elaidi, Laure Fournier, Elizabeth Fabre, Victoria Ferrari, Delphine Borchiellini, Jonathan Thouvenin, Philippe Barthélémy, Constance Thibault, Éric Tartour, Stéphane Oudard, Yann Vano

2020Cancer Immunology Immunotherapy57 citationsDOIOpen Access PDF

Topics & Concepts

MedicineNivolumabInternal medicineRenal cell carcinomaProportional hazards modelLung cancerNeutrophil to lymphocyte ratioProgression-free survivalOncologyCohortRetrospective cohort studyMultivariate analysisCancerGastroenterologyLymphocyteImmunotherapyOverall survivalInflammatory Biomarkers in Disease PrognosisCancer Immunotherapy and BiomarkersLung Cancer Research Studies
Variation in neutrophil to lymphocyte ratio (NLR) as predictor of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (mNSCLC) patients treated with nivolumab | Litcius